PT  - JOURNAL ARTICLE
AU  - Conor C Murphy
AU  - Kathrin Greiner
AU  - Jarka Plskova
AU  - N Andrew Frost
AU  - John V Forrester
AU  - Andrew D Dick
TI  - Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis
AID  - 10.1136/bjo.2006.105528
DP  - 2007 Feb 01
TA  - British Journal of Ophthalmology
PG  - 154--156
VI  - 91
IP  - 2
4099  - http://bjo.bmj.com/content/91/2/154.short
4100  - http://bjo.bmj.com/content/91/2/154.full
SO  - Br J Ophthalmol2007 Feb 01; 91
AB  - Aim: To evaluate the responsiveness of the Vision core module 1 (VCM1) vision-related quality of life (VR-QOL) questionnaire to changes in visual acuity in patients with posterior and intermediate uveitis and to validate its use as a clinical end point in uveitis. Methods: Logarithm of the minimum angle of resolution visual acuity and VR-QOL using the VCM1 questionnaire were prospectively recorded in 37 patients with active posterior segment intraocular inflammation before starting systemic immunosuppression with ciclosporin, tacrolimus or the anti-tumour necrosis factor (TNF) agent, p55TNFr-Ig, and again 3 months later. Spearman analysis was used to correlate improvements in visual acuity and VR-QOL between baseline and 3 months. Results: The correlation between changes in visual acuity and VR-QOL was moderate to good for the worse eye (r = 0.47, p = 0.003), but poor for the better eye (r = −0.05, p = 0.91). The responsiveness indices effect size and standardised response mean were 0.57 and 0.59, respectively, showing that the VCM1 questionnaire is moderately responsive to immunsosuppressive therapy for active uveitis. Conclusion: Changes in VR-QOL measured with the VCM1 questionnaire correlated moderately well with changes in the worse eye visual acuity, suggesting that the VCM1 is a valid instrument for monitoring response to treatment in uveitis.